Priothera Limited
Priothera develops mocravimod, an investigational S1P receptor modulator designed to improve outcomes for patients with hematological malignancies undergoing allogeneic hematopoietic cell transplantation. The therapy aims to enhance the graft-versus-leukemia effect while reducing graft-versus-host disease. The company is also exploring the drug's potential to enhance the curative potential of CAR T cell therapy.
Biotechnology
Healthcare
Oncology
Funding summary
- Total raised
- €30.0M
- Funding rounds
- 1
Investors in Priothera Limited
Investors on record for Priothera Limited. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Priothera Limited?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors